HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX:LCP), an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in large therapeutic areas such as cardiovascular disease, organ transplantation and immunosuppression, including recently Food and Drug Administration approved LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, announced today that Flemming Ornskov, President and Chief Executive Officer, is scheduled to give a company presentation at the G5: ThinkEquity Partners 5th Annual Growth Conference on Thursday, September 20, 2007 at 10:00 a.m. PDT (1:00 p.m. in New York; 7:00 p.m. in Denmark) at the St. Regis Hotel in San Francisco, CA.
